Loading organizations...
§ Private Profile · Skokie, IL, USA
Biotech company developing antigen-specific immunotherapies for autoimmune diseases, focused on immune tolerance.
Cour Pharmaceuticals Development is a Skokie, Illinois-based biotechnology company that develops antigen-specific immunotherapies utilizing polymer nanoparticles to induce immune tolerance for autoimmune diseases. The clinical-stage firm focuses on creating disease-modifying treatments for conditions such as myasthenia gravis and celiac disease by mimicking apoptotic debris without causing broad immune suppression. In early 2024, the enterprise secured $105 million in Series A funding to advance its proprietary clinical pipeline and support ongoing phase two clinical trials. This significant financing round was co-led by Lumira Ventures and Alpha Wave Ventures, with additional strategic participation from the Roche Venture Fund, Pfizer, and Bristol Myers Squibb. Recently named to the BioSpace NextGen Class of 2025, the company transitioned its leadership by appointing Dannielle Appelhans as its new chief executive officer. Cour Pharmaceuticals Development was founded in 2014 by John J. Puisis.
Cour Pharmaceuticals Development has raised $135.0M across 2 funding rounds.
Cour Pharmaceuticals Development has raised $135.0M in total across 2 funding rounds.
Cour Pharmaceuticals Development has raised $135.0M in total across 2 funding rounds.
Cour Pharmaceuticals Development's investors include Alpha Wave Ventures, Benjamin Rovinski, Ph.D., Angelini Ventures, Bristol Myers Squibb, JDRF, Pfizer, Simon Greenwood, Chris Dimitropoulos.
Cour Pharmaceuticals Development has raised $135.0M across 2 funding rounds. Most recently, it raised $105.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 30, 2024 | $105M Series A | Alpha Wave Ventures, Benjamin Rovinski, Ph.d. | Angelini Ventures, Bristol Myers Squibb, JDRF, Pfizer, Simon Greenwood | Announced |
| Sep 7, 2022 | $30M Venture Round | Chris Dimitropoulos | — | Announced |